Literature DB >> 10460271

Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine.

W A Cass1, M W Manning.   

Abstract

Repeated administration of methamphetamine (METH) to animals can result in long-lasting decreases in striatal dopamine (DA) content. In addition, the evoked overflow of striatal DA is reduced in rats 1 week after neurotoxic doses of METH. However, whether these functional changes in DA release are permanent or tend to recover over time has not been established. In the present study we used in vivo electrochemistry and microdialysis to examine evoked overflow of DA in the striatum of METH-treated rats at several time points after treatment to determine if DA overflow would spontaneously recover. Male Fischer-344 rats were administered METH (5 mg/kg, s.c. ) or saline four times in one day at 2 hr intervals. In vivo electrochemistry experiments in anesthetized rats, and in vivo microdialysis studies in awake rats, were carried out 1 week, 1 month, 6 months, and 12 months after treatment. At 1 week after treatment there were significant decreases in potassium- and amphetamine-evoked overflow of DA, and in clearance of DA, in the striatum of the METH-treated animals. Basal extracellular levels of DA and its metabolites were also decreased. Evoked overflow had partially recovered by 1 month. By 6 months evoked overflow of DA appeared to be normal in the METH-treated rats. However, whole tissue levels of striatal DA were still significantly decreased. All parameters were back to control values by 12 months. These results suggest that presynaptic dopaminergic functioning can recover to normal levels in the striatum of METH-treated rats by 12 months after treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460271      PMCID: PMC6782530     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  39 in total

1.  In vivo assessment of dopamine uptake in rat medial prefrontal cortex: comparison with dorsal striatum and nucleus accumbens.

Authors:  W A Cass; G A Gerhardt
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

2.  GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine.

Authors:  W A Cass
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

3.  Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity.

Authors:  S D Friedman; E Castañeda; G K Hodge
Journal:  Pharmacol Biochem Behav       Date:  1998-09       Impact factor: 3.533

4.  Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study.

Authors:  P Cumming; E Brown; G Damsma; H Fibiger
Journal:  J Neurochem       Date:  1992-11       Impact factor: 5.372

5.  Estimating extracellular concentrations of dopamine and 3,4-dihydroxyphenylacetic acid in nucleus accumbens and striatum using microdialysis: relationships between in vitro and in vivo recoveries.

Authors:  S D Glick; N Dong; R W Keller; J N Carlson
Journal:  J Neurochem       Date:  1994-05       Impact factor: 5.372

6.  Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine.

Authors:  K T Finnegan; G Ricaurte; L S Seiden; C R Schuster
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunohistochemical study.

Authors:  C Pu; C V Vorhees
Journal:  Synapse       Date:  1995-02       Impact factor: 2.562

8.  Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine.

Authors:  A J Eisch; M Gaffney; F B Weihmuller; S J O'Dell; J F Marshall
Journal:  Brain Res       Date:  1992-12-11       Impact factor: 3.252

9.  Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system.

Authors:  T E Robinson; Z Mocsary; D M Camp; I Q Whishaw
Journal:  J Neurosci       Date:  1994-05       Impact factor: 6.167

10.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.

Authors:  J P O'Callaghan; D B Miller
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

View more
  31 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Authors:  Seong-Jin Yu; Mikko Airavaara; Hui Shen; Jenny Chou; Brandon K Harvey; Yun Wang
Journal:  Psychopharmacology (Berl)       Date:  2011-12-13       Impact factor: 4.530

3.  Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.

Authors:  Gabriel C Loewinger; Michael V Beckert; Hugo A Tejeda; Joseph F Cheer
Journal:  Neuropharmacology       Date:  2012-01-25       Impact factor: 5.250

4.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

Review 5.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

6.  Short- and long-term effects of (+)-methamphetamine and (+/-)-3,4-methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment.

Authors:  Tori L Schaefer; Matthew R Skelton; Nicole R Herring; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

7.  Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats.

Authors:  Kamisha L Johnson-Davis; Glen R Hanson; Kristen A Keefe
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Phasic-like stimulation of the medial forebrain bundle augments striatal gene expression despite methamphetamine-induced partial dopamine denervation.

Authors:  Christopher D Howard; Elissa D Pastuzyn; Melissa L Barker-Haliski; Paul A Garris; Kristen A Keefe
Journal:  J Neurochem       Date:  2013-04-01       Impact factor: 5.372

9.  Peripheral ammonia and blood brain barrier structure and function after methamphetamine.

Authors:  Nicole A Northrop; Laura E Halpin; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2016-03-10       Impact factor: 5.250

10.  Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Authors:  Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney
Journal:  Neuropsychopharmacology       Date:  2009-07-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.